A 64-year-old woman underwent an ileocecal resection for ileus. The specimen revealed a diffuse large B cell lymphoma. The diagnosis was stage IIA non-Hodgkin's lymphoma. She received chemotherapy with the CHOPetoposide regimen, resulting in partial remission. Highdose etoposide was used for PBSC mobilization before auto-PBSCT. Conditioning was ranimustine, carboplatin, etoposide and cyclophosphamide. Her renal function deteriorated gradually, starting 3 months post-PBSCT. Eight months post-transplant, serum creatine concentration was 7.1 mg/dl, and BUN was 59.2 mg/dl. Her hemoglobin concentration decreased to 5.3 g/dl, with no evidence of hemolysis. Renal biopsy revealed fibrous crescent formations in glomeruli, and mononuclear cell infiltration in interstitial spaces. Renal injury in this patient differs from BMT nephropathy, which is similar to hemolytic uremic syndrome, and represents another type of late renal injury after PBSCT.
Transplantation of either allogeneic or autologous hematopoietic stem cells can be complicated by renal failure from a variety of causes. These complications include not only early but also late renal injury characterized by a syndrome similar to hemolytic uremic syndrome (HUS). [1] [2] [3] [4] [5] We report another type of late renal injury, crescentic glomerulonephritis, which developed more than 3 months after auto-PBSC transplantation (T) for non-Hodgkin's lymphoma.
Case report
A 64-year-old woman, who underwent an ileocecal resection for ileus due to an iliocecal tumor, was diagnosed with , days Ϫ7 to Ϫ4; etoposide 500 mg/m 2 , days Ϫ6 to Ϫ4; and cyclophosphamide 50 mg/kg, days Ϫ3 and Ϫ2). 7 Her serum creatinine (Cr) concentration rose to 1.8 mg/dl (normal range 0.4-0.8 mg/dl) on day 1 (before the conditioning chemotherapy, her serum Cr was 0.5 mg/dl and her Cr clearance was 63.8 ml/min), then returned to baseline on day 6. A complete response was confirmed after PBSCT by whole body CT scan. Three months later, she developed Ramsey-Hunt syndrome. At this time, her serum Cr and BUN concentrations were slightly elevated, to 1.5 mg/dl and 25.6 mg/dl (normal range 6.0-22.0 mg/dl), respectively. She received acyclovir intravenously for 7 days, and the Ramsey-Hunt syndrome improved without sequelae. Beginning in March 1997, anemia and renal dysfunction progressed rapidly, without evidence of a relapse. In June, the Cr and BUN concentrations were 7.1 mg/dl and 59.2 mg/dl, respectively. The hemoglobin concentration decreased to 5.3g/dl. A blood smear showed no evidence of red cell fragmentation, and the laboratory findings showed no evidence of hemolysis. Her platelet count was normal. The serum erythropoietin concentration was 15.7 mU/ml (normal range 12.5-34.5 mU/ml). A 24-h urine analysis revealed 0.4 g protein, with a Cr clearance of 4.0 ml/min. Renal biopsy revealed fibrous crescent formations in the glomeruli, and mononuclear cell infiltration in the interstitial spaces. Intraluminal fibrin thrombi were not seen. Some sclerotic glomeruli were seen (Figure 1 ). Electron microscopy showed swelling of endothelial cells and enlargement of the subendothelial space indicating endothelial damage. Immunofluorescence showed no deposition of immune complexes. Hemolytic complement activity (CH 50 ) was slightly decreased (28.6 U/ml (normal range 30-45 U/ml)). Anti-neutrophil cytoplasmic antigen and circulating anti-glomerular basement membrane antibodies were negative, as was anti-nuclear antigen. The CD4/8 ratio was 0.61. Soluble interleukin-2 (IL-2) receptor concentration was 1370 U/ml. Methylprednisolone pulse therapy was started, followed by oral prednisolone. Her renal dysfunction responded to the steroid therapy. The Cr and BUN concentrations decreased to 3.9 mg/dl and 62 mg/dl, respectively, in August. The anemia also improved with weekly intravenous administration of 6000 units of erythropoietin ( Figure 2 ). Renal insufficiency remains stable with oral prednisolone 10 mg daily. Her lymphoma had been in complete remission for 14 months at the time of this report.
Discussion
A variety of renal lesions may occur in the setting of hematopoietic stem cell transplantation. A distinct syndrome of late renal toxicity, defined as nephrotoxicity developing more than 3 months after transplantation, has been reported by multiple centers that perform BMT with pretransplant TBI. [2] [3] [4] [5] The initial reports of this syndrome described clinical and pathological features similar to HUS. The term 'BMT nephropathy' was used by Cohen et al 2 to describe it. Features include severe hypertension, microangiopathic hemolytic anemia with red cell fragmentation and thrombocytopenia. Renal manifestations include a rapid progressive decline in renal function, significant proteinuria and microscopic hematuria. Light microscopy of renal tissue demonstrates intraluminal fibrin thrombi in glomerular capillaries and renal arterioles. These findings are compatible with HUS. 1 Our case differs from BMT nephropathy in both clinical and pathological respects, and the renal insufficiency was not related to active lymphoma because CR was maintained for more than 11 months after the onset of renal dysfunction. 6, 8 Although the rare occurrence of glomerulonephritis following BMT has been reported previously, those cases were limited to allograft recipients and did not involve crescent formation. 9 Recently, activated T cells expressing IL-2 receptors have been identified in the glomeruli of patients with crescentic glomerulonephritis, suggesting a pathogenic role for these cells. 10 The high titre of IL-2 receptors in our patient was not accompanied by a relapse of her lymphoma, and may be due to the glomerular lesions.
Although the mechanism of the HUS-like lesions seen in BMT nephropathy is not completely understood, the nephropathy in our patient appears to have been caused by a different mechanism of renal injury.
